High Throughput Drug Sensitivity Assay and Genomics- Guided Treatment of Patients With Relapsed or Refractory Acute Leukemia

NACompletedINTERVENTIONAL
Enrollment

34

Participants

Timeline

Start Date

September 11, 2015

Primary Completion Date

June 19, 2020

Study Completion Date

May 13, 2021

Conditions
Recurrent Acute Leukemia of Ambiguous LineageRecurrent Acute Lymphoblastic LeukemiaRecurrent Acute Myeloid LeukemiaRefractory Acute Lymphoblastic LeukemiaRefractory Acute Myeloid LeukemiaRefractory Acute Leukemia of Ambiguous Lineage
Interventions
OTHER

Chemosensitivity Assay

Lab test in which leukemia cells obtained from blood or bone marrow are tested for sensitivity to 115 drugs individually and in certain combinations

OTHER

Cytology Specimen Collection Procedure

Undergo blood or bone marrow collection

GENETIC

Gene Expression Analysis

Analysis of leukemia cell genes to identify possible drug targets

GENETIC

Genetic Variation Analysis

Analysis of leukemia cell genes to identify possible drug targets

DRUG

In Vitro Sensitivity-Directed Chemotherapy

"Receive personalized chemotherapy with one or more of the following drugs:~Afatinib Arsenic trioxide Axitinib Azacitidine Bexarotene Bortezomib Bosutinib Busulfan Cabazitaxel Cabozantinib Carfilzomib Ceritinib Cladribine Clofarabine Crizotinib Cytarabine HCl Dabrafenib Dasatinib Daunorubicin HCl Decitabine Erlotinib Etoposide Everolimus Fludarabine Gefitinib Gemcitabine HCl Hydroxyurea Imatinib Irinotecan Lapatinib Lomustine Melphalan Mercaptopurine Methotrexate Mitoxantrone Nelarabine Nilotinib Paclitaxel Pazopanib Pentostatin Ponatinib Pralatrexate Rapamycin Regorafenib Romidepsin Ruxolitinib Sorafenib Sunitinib Temsirolimus Thioguanine Topotecan HCl Trametinib Tretinoin"

Trial Locations (1)

98109

Fred Hutch/University of Washington Cancer Consortium, Seattle

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

University of Washington

OTHER

NCT02551718 - High Throughput Drug Sensitivity Assay and Genomics- Guided Treatment of Patients With Relapsed or Refractory Acute Leukemia | Biotech Hunter | Biotech Hunter